It has central antiadrenergic, antidopaminergic, antiserotonergic and weak muscarinic anticholinergic effects.

 
Serious side effects include [[akathisia]], [[tardive dyskinesia]] and the potentially fatal [[neuroleptic malignant syndrome]].

 
Mesoridazine was withdrawn from the United States market in 2004 due to dangerous side effects, namely irregular heart beat and QT-prolongation of the electrocardiogram.<ref>[http://www.nlm.nih.gov/medlineplus/druginfo/medmaster/a682306.html]</ref>
